| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -4.6 | -7.1 |
| EPS (diluted, $ a share) | $-288.89 | $-1,779,500.00 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CDT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
CDT Equity Inc.: key numbers
- Share price
- $0.3770Close, Nov 16
- Market cap
- $2.38M
- Shares outstanding
- 6.31MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from CDT Equity Inc.
All →CDT Equity Reverse Stock Split
CDT Equity Inc. stockholders approved a proposal to authorize the board of directors to effect a reverse stock split at a ratio ranging from 1-for-2 to 1-for-100. Stockholders also approved the issuance of common stock under Nasdaq Listing Rule 5635 related to convertible notes and warrants issued to J.J. Astor & Co.
CDT Equity M&A Deal with Corvus Capital Limited
CDT Equity Inc. received a letter from former CEO Dr. Andrew Regan and Corvus Capital Limited indicating an intent to propose a non-binding acquisition of all outstanding common stock at $2.00 per share. The Board of Directors plans to form a Special Committee of independent directors to evaluate the potential proposal and other strategic alternatives.
- Counterparty
- Corvus Capital Limited
CDT Equity Reverse Stock Split
CDT Equity Inc. has filed a certificate of amendment to effectuate a 1-for-20 reverse stock split of its common stock, effective November 5, 2026. The split is intended to maintain compliance with Nasdaq Listing Rules, reducing the outstanding share count from approximately 20.4 million to 1.0 million shares. Trading on a split-adjusted basis is expected to begin on November 6, 2026, under the existing ticker symbol 'CDT'.
CDT Equity Business Update
CDT Equity entered into an evaluation agreement with Manoira Corporation to analyze clinical-stage compounds AZD1656 and AZD5904 for potential use in animal health products. As part of the arrangement and other corporate obligations, the company issued shares to Manoira to settle a $195,000 payment, as well as shares to a service provider and former CEO Dr. Andrew Regan for severance.
- Counterparty
- Manoira Corporation
CDT Equity $6.75M Debt Financing with J.J. Astor & Co.
CDT Equity Inc. issued a $6.75 million senior secured convertible promissory note to J.J. Astor & Co., to be funded in two tranches. The note is secured by a first priority lien on company assets and includes weekly installment payments starting October 14, 2026. The lender has the right to convert the debt into common stock at a discount to the market price, subject to a floor price of $0.18354.
- Value
- $6.75M
- Counterparty
- J.J. Astor & Co.
- Term
- through March 24, 2027
CDT Equity Reverse Stock Split
CDT Equity Inc. has announced a 1-for-25 reverse stock split of its common stock, effective September 28, 2026. The split is intended to increase the per-share price to ensure continued compliance with the Nasdaq minimum bid-price requirement. Trading on a split-adjusted basis is expected to begin on September 29, 2026, reducing the outstanding share count to approximately 1.12 million shares.